indications including depression, anxiety disorders, insomnia, multiple sclerosis, borderline personality disorder, epilepsy, oncology, rheumatoid arthritis, alcohol use disorder, ADHD, and burnout. Products are CE-marked medical devices available across Europe and the United States, and in Germany listed as prescribable, insurer-reimbursed DiGAs (Digitale Gesundheitsanwendungen).

Currently active products include: deprexis® (depression), velibra® (anxiety disorders), somnovia® (insomnia), elevida® (MS fatigue), levidex® (multiple sclerosis), priovi® (borderline personality disorder), vorvida® (alcohol use disorder), attexis® (adult ADHD), and MODIA (opioid use disorder, US market). All products are CE-marked medical devices available to patients and providers across Europe and the United States.

The clinical evidence base is what truly distinguishes GAIA: more than 60 clinical studies, with results published in The Lancet Psychiatry, The Lancet Digital Health, JAMA Psychiatry, npj Digital Medicine, Psychological Medicine, and BMJ, among others. GAIA's flagship product deprexis® — an internet-based treatment for depression — has been studied in 13 RCTs alone, with effect sizes comparable to antidepressant medication.

GAIA has a meaningful US presence on three levels: a wholly owned subsidiary (GAIA America Inc.) headquartered in New York; US-based RCTs, including a pivotal deprexis® trial in 376 American adults (d = 0.80; Journal of Consulting and Clinical Psychology, 2017) and a Phase 3 MS trial conducted across academic centers in Germany and the United States (The Lancet Digital Health, 2023); and active research partnerships with institutions including the University of Texas at Austin, VA Palo Alto, and university medical centers in Los Angeles, Pennsylvania, and Missouri.

GAIA partners with leading pharmaceutical companies, statutory health insurers, and payer organizations globally on co-development, licensing, and patient support programs.